Anthem Biosciences share price gains after strong listing. Should you buy, sell or hold the stock?

Anthem Biosciences share price made a stellar debut in the Indian stock market today, July 21, after its initial public offering (IPO) received a strong demand. Anthem Biosciences shares listed at ₹723.05 apiece on the NSE, a premium of 26.85% over the issue price of ₹570 per share.

On BSE, Anthem Biosciences share price opened at ₹723.10 apiece, higher by 26.86% from the IPO price.

Anthem Biosciences is a manufacturer of specialised fermentation-based APIs, and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, July 21, 2025.

Anthem Biosciences IPO listing was in line with the Street estimates, as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today, and analysts had signalled a strong debut of shares.

Here’s what investors should do after Anthem Biosciences' share listing today.

Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities, advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management.

“Long-term investors should focus on the company’s growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilises, it may offer a better entry point based on earnings visibility and peer comparison,” Ojha said.

According to Prashanth Tapse, Sr. VP Research at Mehta Equities, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite.

“While post-listing valuations may appear premium, we believe these are justified by the company’s strong fundamentals, differentiated capabilities, and the sector’s long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,” Tapse said.

Hence, looking at its all financial as well as sectorial, he recommends investors to “Hold” Anthem Biosciences shares for a long-term perspective.

“For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. In the short term, we foresee ₹900 as the target for Anthem shares, while long-term investors can hold it for ₹1,000 and above. Non-allottees can wait for some volatility to settle in price, and in any case, if the stock is available around ₹650-680, it can be considered a good range to accumulate with a long-term vision,” Tapse said.

Shivani Nyati, Head of Wealth at Swastika Investmart, recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹650.

Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non-Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription.

At 12:25 PM, Anthem Biosciences' share price was trading at ₹728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price.

Read all IPO news here

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Download the Mint app and read premium stories